Roundup

Roundup is one of the largest and most closely watched mass torts in the federal system, and its funding profile reflects a docket that is active and unresolved despite a major settlement already in its history. Bayer's June 2020 global settlement resolved a large share of the historical claim population for a combined $8.8 to $9.6 billion, plus $1.5 billion set aside for future claims, but that settlement excluded certain already-appealed cases, and reporting from 2023 indicated a substantial number of claims, over 50,000, remained pending even after that settlement. With 3,925 actions currently coordinated in the Northern District of California, this remains a docket with real, ongoing claim volume rather than a wound-down legacy matter.

For funders and portfolio-finance allocators, the central complicating factor is a 2024 federal circuit split on whether FIFRA preempts state-law failure-to-warn claims, with the Third Circuit finding preemption in conflict with prior Ninth and Eleventh Circuit rulings. That unresolved legal question, which carries real potential for U.S. Supreme Court review, materially affects claim value and timeline depending on which circuit's law governs a given claim, and it should be built explicitly into any pricing model rather than treated as a background risk.

Bellwether trial results reported through late 2023 showed Bayer prevailing in the substantial majority of trials that reached verdict, which is relevant context for underwriting individual claim strength, though funders should confirm the current trial record rather than rely on outcomes from several years earlier, since bellwether programs in a docket this size continue to evolve. Reports as of mid-2025 also indicated Bayer was weighing further settlement measures, including a possible bankruptcy filing for its Monsanto subsidiary, which would materially change the resolution landscape if it occurs.

Medical-lien considerations remain significant for the underlying non-Hodgkin lymphoma claims. Given the number of live variables here, Criterica Capital's mass tort finance product applies pricing that explicitly accounts for circuit-specific preemption exposure, and Criterica Intelligence's structural brief on this docket's litigation and settlement posture is the right starting point before committing capital at scale.

A 2024 circuit split emerged on whether the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) preempts state-law failure-to-warn claims: the Third Circuit found preemption, conflicting with prior Ninth and Eleventh Circuit rulings that found no preemption, a conflict that increases the likelihood of U.S. Supreme Court review of the question.

Pre-settlement funding is a non-recourse purchase of a portion of the proceeds of a pending legal claim — not a loan. If the case does not result in a recovery, nothing is owed. Rates, fees, and repayment terms are disclosed in full in the funding agreement, which the applicant’s attorney reviews before signing. Availability and terms vary by state.